查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026739

結核病診斷市場預測至2034年－按產品類型、檢測類型、疾病階段、最終用戶和地區分類的全球分析

Tuberculosis Diagnostics Market Forecasts to 2034 - Global Analysis By Product Type, Test Type, Disease Stage, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球結核病診斷市場規模將達到 25.8 億美元，並在預測期內以 7.6% 的複合年成長率成長，到 2034 年將達到 46.4 億美元。

結核病（TB）是由結核分枝桿菌引起的傳染病，主要涉及患者的肺部、脊椎和腦部。結核病診斷能夠客觀、準確地辨識結核病感染。這有助於將結核病與其他具有相似症狀的呼吸道疾病區分開來，從而減少誤診和不必要的治療。

根據世界衛生組織發布的《2022年世界結核病報告》，2021年全球約有1,060萬人罹患結核病，比2020年報告的1,010萬例增加了4.5%。

抗藥性結核病

抗藥性菌株（例如多重抗藥性結核病 (MDR-TB) 和廣譜抗藥性結核病 (XDR-TB)）的出現，使得準確快速的診斷檢測需求日益成長。由於抗藥性結核菌對第一線抗結核藥物無效，因此對其進行檢測和適當治療至關重要。傳統的診斷方法可能無法識別抗藥性菌株，導致治療延遲、療效降低、感染擴散以及患者預後不良。因此，人們越來越需要能夠準確檢測抗藥性結核病的先進診斷方法。

高成本

分子檢測和基因分型等先進診斷技術通常比痰液塗片顯微鏡檢查等傳統方法成本更高。這些成本不僅包括檢測套組本身，還包括必要的設備、檢查室基礎設施和專業人員。因此，高成本可能會阻礙醫療機構採用更先進、更精準的診斷技術，進而可能抑制市場成長。

先進的診斷技術

透過利用聚合酵素鏈鎖反應(PCR) 和核酸增幅檢查(NAAT) 等分子技術，可以提高檢測靈敏度，即使在細菌量較低的情況下也能檢測到結核病。此外，就地檢驗的進步使患者更容易獲得診斷。這在資源匱乏的環境中尤其有利，因為它縮短了從開始治療到獲得結果的時間。因此，這些先進的診斷技術將加速市場成長。

柱頭

對傳播途徑的誤解、對感染的恐懼以及與貧困和弱勢群體的關聯，都加劇了結核病的污名。然而，這種污名化可能導致人們不願透露自身症狀、尋求醫療協助或接受結核病診斷檢測。人們可能因為害怕被社會排斥、歧視或遭受負面社會評價而不敢接受結核病診斷服務。這會導致診斷延誤和疾病傳播。這些因素都阻礙了市場需求。

新冠疫情的感染疾病

新冠疫情對結核病診斷市場產生了重大影響。疫情初期，醫療衛生系統運作受阻，導致結核病診斷資源被分散，但也凸顯了健全的診斷基礎設施的重要性。隨著疫情逐漸消退，人們日益認知到加強醫療衛生系統的必要性，這可能為結核病診斷帶來長期的益處。此外，新冠疫情可能加速了遠距遠端醫療和數位醫療的發展，進而提升結核病診斷能力。

在預測期內，診斷檢查室方法學領域預計將佔據最大佔有率。

診斷檢測領域預計將佔據最大的市場佔有率。全球大多數醫院和診所都提供培養和塗片顯微鏡檢查。因此，對於可能無法獲得更先進診斷程序的患者而言，這些仍然是診斷結核病的有效選擇。此外，儘管核酸增幅檢查（NAAT）等新型檢測方法正變得越來越普及，但塗片顯微鏡檢查和培養檢測仍然被認為是診斷結核病最準確的方法。

在預測期內，痰液塗片顯微鏡檢查領域預計將呈現最高的複合年成長率。

預計在預測期內，痰液塗片顯微鏡檢查市場將顯著成長。這是一種簡單且經濟有效的檢測痰液檢體中抗酸桿菌（AFB）的方法，可用於診斷結核病。痰液塗片顯微鏡檢查無需先進的實驗室設施或昂貴的設備，因此即使在資源匱乏的環境中也能廣泛應用。此外，此方法能夠快速提供結果，使醫護人員能夠及時啟動結核病治療，防止感染擴散，並改善患者預後。

市佔率最大的地區：

亞太地區結核病發生率高且傳播迅速，因此佔據市場主導地位，市佔率最大。該地區多個國家結核病發病率的上升是推動市場收入成長的主要因素之一。此外，該地區的高死亡率和較低的人類發展指數也是支撐市場收入成長的重要因素。受影響的國家包括孟加拉、中國、印度、印尼、巴基斯坦和菲律賓。

複合年成長率最高的地區：

在北美，成人和兒童結核病患者的上升預計將在預測期內推動市場盈利成長。該地區的醫學研究機構正在發現與病原體特異性代謝途徑相關的諸多優勢，這些優勢可作為現有方法的替代方案，現有方法著重於檢測病原體免疫反應、細菌生長或細菌核酸擴增。此外，人工智慧與奈米技術的結合也顯著促進了北美結核病患者診斷流程的改進。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球結核病診斷市場：依產品類型分類

  • 痰液塗片顯微鏡檢查
  • 基於培養的診斷方法
  • 快速分子診斷
  • 其他產品類型

第6章：全球結核病診斷市場：依檢測類型分類

  • 檢測潛伏性行為感染
  • X光檢查
  • 核酸檢測
  • 噬菌體檢測
  • 檢查室診斷方法
  • 檢測抗藥性
  • 細胞激素檢測分析
  • 其他測試類型

第7章 全球結核病診斷市場：依疾病進展階段分類

  • 活動性肺結核
  • 潛伏性結核病

第8章 全球結核病診斷市場：依最終用戶分類

  • 臨床檢查室
  • 醫院/診斷檢查室
  • 測試機構
  • 學術機構及研究設施
  • 其他最終用戶

第9章 全球結核病診斷市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Becton Dickinson and Company
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Oxford Immunotec Ltd.
  • Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • BioMerieux SA
  • Akonni Biosystems Inc.
  • Cepheid Inc.
  • Alere Inc.
  • PAR Pharmaceuticals
  • Hain Life Science.
  • Lionex GmbH
Product Code: SMRC24677

According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.58 billion in 2026 and is expected to reach $4.64 billion by 2034 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.

According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.

Market Dynamics:

Driver:

Drug-resistant TB

The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.

Restraint:

High cost

Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.

Opportunity:

Advanced diagnostic technologies

The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.

Threat:

Stigma

Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.

The diagnostic laboratory methods segment is expected to be the largest during the forecast period

The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.

The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period

The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.

Region with largest share:

Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.

Key players in the market

Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.

Key Developments:

In February 2022 - QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.

In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.

Product Types Covered:

  • Sputum Smear Microscopy
  • Culture-Based Diagnostics
  • Rapid Molecular Diagnostics
  • Other Product Types

Test Types Covered:

  • Detection of Latent Infection
  • Radiographic Method
  • Nucleic Acid Testing
  • Phage Assay
  • Diagnostic Laboratory Methods
  • Detection of Drug Resistance
  • Cytokine Detection Assay
  • Other Test Types

Disease Stages Covered:

  • Active Tuberculosis
  • Latent Tuberculosis

End Users Covered:

  • Physician's Office Laboratories
  • Hospitals and Diagnostic Laboratories
  • Reference Laboratories
  • Academics and Research Facilities
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tuberculosis Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Sputum Smear Microscopy
  • 5.3 Culture-Based Diagnostics
  • 5.4 Rapid Molecular Diagnostics
  • 5.5 Other Product Types

6 Global Tuberculosis Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Detection of Latent Infection
  • 6.3 Radiographic Method
  • 6.4 Nucleic Acid Testing
  • 6.5 Phage Assay
  • 6.6 Diagnostic Laboratory Methods
  • 6.7 Detection of Drug Resistance
  • 6.8 Cytokine Detection Assay
  • 6.9 Other Test Types

7 Global Tuberculosis Diagnostics Market, By Disease Stage

  • 7.1 Introduction
  • 7.2 Active Tuberculosis
  • 7.3 Latent Tuberculosis

8 Global Tuberculosis Diagnostics Market, By End User

  • 8.1 Introduction
  • 8.2 Physician's Office Laboratories
  • 8.3 Hospitals and Diagnostic Laboratories
  • 8.4 Reference Laboratories
  • 8.5 Academics and Research Facilities
  • 8.6 Other End Users

9 Global Tuberculosis Diagnostics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Becton Dickinson and Company
  • 11.2 Qiagen NV
  • 11.3 Thermo Fisher Scientific Inc.
  • 11.4 Oxford Immunotec Ltd.
  • 11.5 Hoffmann-La Roche Ltd.
  • 11.6 Hologic Inc.
  • 11.7 BioMerieux SA
  • 11.8 Akonni Biosystems Inc.
  • 11.9 Cepheid Inc.
  • 11.10 Alere Inc.
  • 11.11 PAR Pharmaceuticals
  • 11.12 Hain Life Science.
  • 11.13 Lionex GmbH

List of Tables

  • Table 1 Global Tuberculosis Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 4 Global Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 5 Global Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 6 Global Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 7 Global Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 8 Global Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 9 Global Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 10 Global Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 11 Global Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 12 Global Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 13 Global Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 14 Global Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 15 Global Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 16 Global Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 17 Global Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 18 Global Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 19 Global Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 20 Global Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 21 Global Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 22 Global Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 23 Global Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 24 Global Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 25 North America Tuberculosis Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 26 North America Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 27 North America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 28 North America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 29 North America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 30 North America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 31 North America Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 32 North America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 33 North America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 34 North America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 35 North America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 36 North America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 37 North America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 38 North America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 39 North America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 40 North America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 41 North America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 42 North America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 43 North America Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 44 North America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 45 North America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 46 North America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 47 North America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 48 North America Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 49 Europe Tuberculosis Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 50 Europe Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 51 Europe Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 52 Europe Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 53 Europe Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 54 Europe Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 55 Europe Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 56 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 57 Europe Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 58 Europe Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 59 Europe Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 60 Europe Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 61 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 62 Europe Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 63 Europe Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 64 Europe Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 65 Europe Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 66 Europe Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 67 Europe Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 68 Europe Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 69 Europe Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 70 Europe Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 71 Europe Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 72 Europe Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 73 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 74 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 75 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 76 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 77 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 78 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 79 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 80 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 81 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 82 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 83 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 84 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 85 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 86 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 87 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 88 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 89 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 90 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 91 Asia Pacific Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 92 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 93 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 94 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 95 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 96 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 97 South America Tuberculosis Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 98 South America Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 99 South America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 100 South America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 101 South America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 102 South America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 103 South America Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 104 South America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 105 South America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 106 South America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 107 South America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 108 South America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 109 South America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 110 South America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 111 South America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 112 South America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 113 South America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 114 South America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 115 South America Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 116 South America Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 117 South America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 118 South America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 119 South America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 120 South America Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 121 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Country (2023-2034) ($MN)
  • Table 122 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 123 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2023-2034) ($MN)
  • Table 124 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2023-2034) ($MN)
  • Table 125 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2023-2034) ($MN)
  • Table 126 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Product Types (2023-2034) ($MN)
  • Table 127 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 128 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2023-2034) ($MN)
  • Table 129 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2023-2034) ($MN)
  • Table 130 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2023-2034) ($MN)
  • Table 131 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Phage Assay (2023-2034) ($MN)
  • Table 132 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2023-2034) ($MN)
  • Table 133 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2023-2034) ($MN)
  • Table 134 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2023-2034) ($MN)
  • Table 135 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 136 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Disease Stage (2023-2034) ($MN)
  • Table 137 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2023-2034) ($MN)
  • Table 138 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2023-2034) ($MN)
  • Table 139 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 140 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Physician's Office Laboratories (2023-2034) ($MN)
  • Table 141 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2023-2034) ($MN)
  • Table 142 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2023-2034) ($MN)
  • Table 143 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2023-2034) ($MN)
  • Table 144 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)